{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:38:33Z","timestamp":1769006313193,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04150-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:16:15Z","timestamp":1765602975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiang","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"1","key":"4150_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"4150_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-2600(24)00223-6","volume":"12","author":"FL Schneiders","year":"2024","unstructured":"Schneiders FL, Senan S. New strategies for patients with limited-stage small-cell lung cancer. Lancet Respir Med. 2024;12(10):748\u201350.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"4150_CR3","doi-asserted-by":"publisher","first-page":"e2440673","DOI":"10.1001\/jamanetworkopen.2024.40673","volume":"7","author":"MK Farris","year":"2024","unstructured":"Farris MK, Mix MD, Wang X, Jaszewski B, Foster N, Masters GA, et al. Prognostic factors in limited-stage small cell lung cancer: a secondary analysis of CALGB 30610-RTOG 0538. JAMA Netw Open. 2024;7(10):e2440673.","journal-title":"JAMA Netw Open"},{"issue":"13","key":"4150_CR4","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.22.02316","volume":"41","author":"MP Deek","year":"2023","unstructured":"Deek MP, Haigentz M, Jabbour SK. Waiting for big changes in limited-stage small-cell lung cancer: for now, more of the same. J Clin Oncol. 2023;41(13):2326\u201330.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4150_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330.","journal-title":"J Clin Oncol"},{"issue":"10212","key":"4150_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"issue":"1","key":"4150_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","volume":"23","author":"M Xie","year":"2024","unstructured":"Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O\u2019Brien C, et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024;23(1):115.","journal-title":"Mol Cancer"},{"issue":"10495","key":"4150_CR8","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","volume":"405","author":"L Paz-Ares","year":"2025","unstructured":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405(10495):2129\u201343.","journal-title":"Lancet"},{"issue":"14","key":"4150_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"4150_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Pujol JL, Dafni U, D\u00f3mine M, Popat S, Reck M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial. Ann Oncol. 2022;33(1):67\u201379.","journal-title":"Ann Oncol"},{"issue":"2","key":"4150_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4150_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"4150_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PIC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"4150_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the journal of clinical epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"7_Supplement","key":"4150_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT255","volume":"84","author":"Y Gong","year":"2024","unstructured":"Gong Y, Pang Q, Yu R, Zhu ZF, Huang JQ, Cheng YF, et al. Abstract CT255: AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT)\u2009+\u2009tislelizumab (anti-PD-1)\u2009+\u2009concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC). Cancer Res. 2024;84(7_Supplement):CT255-CT255.","journal-title":"Cancer Res"},{"key":"4150_CR16","doi-asserted-by":"crossref","unstructured":"Ni J, Ren SX, Xu XL, Hu M, Xu QH, Chen Y et al. Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer. J Clin Oncol. 2024;42:16_suppl, e20132-e20132.","DOI":"10.1200\/JCO.2024.42.16_suppl.e20132"},{"key":"4150_CR17","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1200\/JCO.2024.42.16_suppl.8098","volume":"42","author":"PX Zhang","year":"2024","unstructured":"Zhang PX, Liu FJ, Wang DQ, Zheng SY, Guo JY, Zou YY, et al. A randomized phase II study of Toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer. J Clin Oncol. 2024;42:8098\u20138098.","journal-title":"J Clin Oncol"},{"key":"4150_CR18","doi-asserted-by":"crossref","unstructured":"Gronberg BH, Aanerud M, Dumoulin DW, Nyman J, Schytte T, Bjaan\u00e6s MM et al. Randomized phase II trial investigating whether Atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). J Clin Oncol. 2025;43:17_suppl.LBA8005.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8005"},{"issue":"5","key":"4150_CR19","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ijrobp.2024.02.063","volume":"119","author":"GM Walls","year":"2024","unstructured":"Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O\u2019Brien M, et al. Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial. Int J Radiat Oncol Biol Phys. 2024;119(5):1386\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"4150_CR20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19(7):1073\u201385.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4150_CR21","doi-asserted-by":"publisher","first-page":"e35849","DOI":"10.1002\/cncr.35849","volume":"131","author":"C Dennehy","year":"2025","unstructured":"Dennehy C, Conroy MR, Forde PM. Immunotherapy for resectable lung cancer. Cancer. 2025;131(10):e35849.","journal-title":"Cancer"},{"issue":"1","key":"4150_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jtho.2018.11.005","volume":"14","author":"J van Loon","year":"2019","unstructured":"van Loon J, Dingemans AC. Is concurrent chemoradiotherapy also the best treatment for elderly patients with limited-stage small cell lung cancer? - what the CONVERT data can tell us. J Thorac Oncol. 2019;14(1):13\u20135.","journal-title":"J Thorac Oncol"},{"key":"4150_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.06.029","volume":"137","author":"JM Mankor","year":"2020","unstructured":"Mankor JM, Zwierenga F, Dumoulin DW, Neefjes JJC, Aerts JGJV. A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: did we choose the optimal chemotherapy backbone? Eur J Cancer. 2020;137:40\u20134.","journal-title":"Eur J Cancer"},{"key":"4150_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2023.02.004","volume":"90","author":"A Saxena","year":"2023","unstructured":"Saxena A. Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer. Semin Cancer Biol. 2023;90:45\u201356.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"4150_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41419-021-04356-6","volume":"12","author":"J Pan","year":"2021","unstructured":"Pan J, Qiao Y, Chen C, Zang H, Zhang X, Qi F, et al. USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1. Cell Death Dis. 2021;12(11):1051.","journal-title":"Cell Death Dis"},{"key":"4150_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2668","author":"I Sam","year":"2025","unstructured":"Sam I, Ben Hamouda N, Alkatrib M, Gonnin C, Siska PJ, Oudard S, et al. The CD70-CD27 axis in cancer immunotherapy: predictive biomarker and therapeutic target. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2668.","journal-title":"Clin Cancer Res"},{"key":"4150_CR27","doi-asserted-by":"publisher","first-page":"107327482513344","DOI":"10.1177\/10732748251334434","volume":"32","author":"X Jin","year":"2025","unstructured":"Jin X, Zhao W, Li G, Jiang J. Immunotherapy for limited-stage small cell lung cancer: innovative treatments and future perspectives. Cancer Control. 2025;32:10732748251334434.","journal-title":"Cancer Control"},{"issue":"9","key":"4150_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.6004\/jnccn.2025.7034","volume":"23","author":"HI Lee","year":"2025","unstructured":"Lee HI, Noh JM, Lee TH, Choi EK, Kim SS, Shin YS, et al. Refining patient selection for prophylactic cranial irradiation in limited-stage SCLC: a multicenter cohort study. J Natl Compr Canc Netw. 2025;23(9):371\u20138.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4150_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2024.11.011","volume":"20","author":"A Levy","year":"2025","unstructured":"Levy A, Rusthoven CG, Brown PD, Le P\u00e9choux C, Faivre-Finn C. Prophylactic cranial irradiation for patients with SCLC-a new perspective in the immunotherapy era. J Thorac Oncol. 2025;20(3):395\u20138.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"4150_CR30","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4150_CR31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00261-018-1752-4","volume":"44","author":"B Morse","year":"2019","unstructured":"Morse B, Jeong D, Ihnat G, Silva AC. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. Abdom Radiol. 2019;44(2):766\u201374.","journal-title":"Abdom Radiol"},{"issue":"4","key":"4150_CR32","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s00330-024-11060-4","volume":"35","author":"C Nelles","year":"2025","unstructured":"Nelles C, Gr\u00e4f M, Bernard P, Persigehl T, Gro\u00dfe Hokamp N, Zopfs D, et al. Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients. Eur Radiol. 2025;35(4):2084\u201393.","journal-title":"Eur Radiol"},{"issue":"13","key":"4150_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413125","volume":"12","author":"L Wu","year":"2025","unstructured":"Wu L, Zhang Z, Jiang C, Li L, Sun X, Bai M, et al. Integration of circulating tumor DNA and metabolic parameters on <Superscript>18<\/Superscript>F-fludeoxyglucose positron emission tomography for outcome prediction in unresectable locally advanced non-small cell lung cancer. Adv Sci. 2025;12(13):e2413125.","journal-title":"Adv Sci"},{"issue":"5","key":"4150_CR34","doi-asserted-by":"publisher","first-page":"e011545","DOI":"10.1136\/jitc-2025-011545","volume":"13","author":"Z Quandt","year":"2025","unstructured":"Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, et al. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. J Immunother Cancer. 2025;13(5):e011545.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4150_CR35","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0101","volume":"31","author":"T Barlas","year":"2024","unstructured":"Barlas T, Sutcuoglu O, Akdogan O, Balos Toruner F, Akturk M, Ozdemir N, et al. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center. Endocr Relat Cancer. 2024;31(11):e240101.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4150_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pccm.2024.12.001","volume":"3","author":"Y Xu","year":"2025","unstructured":"Xu Y, Chen R, Pan R, Gao X, Huang H, Wang M. Clinical management of checkpoint inhibitor pneumonitis: focus, challenges, and future directions. Chin Med J Pulm Crit Care Med. 2025;3(1):29\u201340.","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"5","key":"4150_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/1750743X.2025.2488728","volume":"17","author":"X Hu","year":"2025","unstructured":"Hu X, Rodday AM, Gurinovich A, Pan S, Salei YV, Lin JH, et al. Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors. Immunotherapy. 2025;17(5):321\u20139.","journal-title":"Immunotherapy"},{"key":"4150_CR38","doi-asserted-by":"publisher","first-page":"1538392","DOI":"10.3389\/fimmu.2025.1538392","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Cao L, Liu L, Ding Y, Cao F. Peripheral blood markers predict prognosis and IrAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs. Front Immunol. 2025;16:1538392.","journal-title":"Front Immunol"},{"issue":"1","key":"4150_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12890-025-03742-6","volume":"25","author":"X Wang","year":"2025","unstructured":"Wang X, Fu X, Liu Q, Li J, Ge Y, Zhang J, et al. Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC. BMC Pulm Med. 2025;25(1):283.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"4150_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ijrobp.2024.01.217","volume":"119","author":"C Han","year":"2024","unstructured":"Han C, Qiu J, Bai L, Liu T, Chen J, Wang H, et al. Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2024;119(4):1179\u2013207.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04150-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:02:47Z","timestamp":1768953767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04150-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4150"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04150-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the nature of this study no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}